Spearheading Affordable Access & Driving Value with Innovative Payment Models & Reimbursement Solutions to Advance Coverage of Transformative Cell & Gene Therapies to Patients in Need
The cell and gene therapy sector is accelerating faster than the systems designed to pay for it. With 39 FDA approved CGTs and more than 80 expected by 2032, the widening gap between scientific progress and pricing, policy, and reimbursement frameworks is threatening real world patient access. At the same time, the last year has brought major changes, from the Cell and Gene Therapy Access Model and outcomes based agreements to rising concerns about coverage and the policy changes still to come.
Returning to Washington DC, the 3rd Cell & Gene Therapy Pricing & Reimbursement Summit is the only meeting built specifically for cell and gene therapy biopharma, commercial and government payers, policymakers, and healthcare providers to confront these challenges head on. Through exclusive case studies from newly commercialized companies, deep dives into the latest policy shifts, and practical frameworks for value communication, you’ll gain the insights needed to navigate the current commercialization landscape and be part of the conversation discussing what policy changes will be needed next.
Join the stakeholders defining the future of cell and gene therapy affordability, and leave with the strategies to secure coverage, expand treatment capacity, and unlock patient access in 2026 and beyond.
Great conference on an extremely important topic. Presentations were very good and thought-provoking.
Head of Market Access, CSL, 2025 Speaker
Great line up of speakers, very relevant topics and actionable insights. Also, appreciated networking opportunities.
Vice President, Business Analytics, Neurogene, 2024 Attendee
It is critical for all stakeholders to find workable solutions that balance access to cutting-edge gene therapies and cellular immunotherapies for patients with affordable financing and coverage. Summits like this are essential to making that a reality.
Managing Director, Legislative & Regulatory Policy, Blue Cross Blue Shield Association, 2026 Speaker
Explore the Full Event Guide
- 20+ speakers from leading cell and gene manufacturers, healthcare providers, commercial and government payers, and policy experts
- Network with 80+ like-minded professionals focussed on addressing the latest policy and commercialisation challenges for cell and gene therapies
- Hear case studies from involvement with the Cell and Gene Therapy Access Model, and the latest on launching a product in 2025
- The only meeting exclusively dedicated to market access, pricing, and reimbursement challenges for cell and gene therapies
Official Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Dive into the only agenda that unpacks real world cell and gene therapy pricing, reimbursement, evidence generation, payer strategy, and policy shifts shaping market viability today.
Partner With Us
Position your solutions at the center of cell and gene therapy market access, payer engagement, and commercialization strategy conversations attended by the field’s leading decisionmakers.
Join Biopharma Experts
Network with the manufacturers, payers, policy leaders, and access strategists defining the future of cell and gene therapy coverage, affordability, and sustainable patient access.